FORCE’s eXamining the Relevance of Articles for Young Survivors (XRAYS) program is a reliable resource for breast cancer research-related news and information. XRAYS reviews new breast cancer research, provides plain-language summaries, and rates how the media covered the topic. XRAYS is funded by the CDC.
Alejandra Campoverdi comes from a family with three generations of breast cancer. As a former White House aide and active educator in the Latina community, she has openly shared her story of genetic testing, her BRCA2 mutation and her plans for risk-reducing mastectomy at age 39. (6/6/19)
The American Society of Breast Surgeons published statement on genetic testing for hereditary breast cancer on February 10, 2019. It includes recommendations about who should be tested. Among these is the recommendation that all breast cancer patients get genetic testing, as well as women who do not have breast cancer but fit the National Comprehensive Cancer Network (NCCN) guidelines. (3/25/19)
A study showed that African American women experienced greater burdens in obtaining information at each step compared to white women. Racial differences in preventive choices correlated with differences in information and provider access. (3/14/19)
Several recent studies on the cost of cancer care show the negative effects on cancer patients. In this XRAYS we review a recent article by Kaiser Health News and associated studies about the financial impact of breast cancer treatment and cost of precision medicine. (2/8/19)
It is well documented that many BRCA mutation carriers are missed using current family history-based screening approaches. As a result, experts are beginning to call for population-based
BRCA genetic testing—an organized effort to screen all women like we do for breast and cervical cancer. A recent study looked at whether a population-based genetic testing approach would better identify mutation carriers compared with current practice. (11/17/18)
For women at average risk of breast cancer, the United States Preventive Services Task Force (USPSTF) currently recommends beginning annual breast cancer screening at age 50. However, because these guidelines are largely based on data from white women, they may not be sensitive to racial differences. A new study assesses the age distribution of breast cancer cases across race/ethnicity in the U.S. (6/21/18)
A research study published in Genetics in Medicine earlier this year shows that women with mutations in MSH6 and PMS2, two Lynch syndrome genes, have a modest (2 to 3-fold) but significantly increased risk for breast cancer.
Lynch syndrome mutations have a known risk of colorectal, ovarian and uterine/endometrial cancer, as well as many other cancers. This is the first study to evaluate breast cancer risk in women with mutations in specific Lynch syndrome genes. (6/14/18)
In this follow-up, we update a recent XRAYS on expanded genetic testing in Jewish women with breast cancer. An expert in the field suggests a different interpretation of the original study than the authors. We examine the key differences in interpretation of the data. (6/7/18)
The risk of breast cancer is exceptionally high in women who have a personal or family history of breast cancer or who carry a mutation in BRCA or certain other genes. More frequent screening is one strategy for early detection of breast cancer for these women. Study results presented at the 2017 San Antonio Breast Cancer Symposium suggest that MRI screening every 6 months may be more effective than the currently recommended annual breast
MRI and annual mammogram in detecting early stage breast cancers-which are more treatable-in high-risk women. (2/1/18)
Korin Miller’s piece for SELF magazine focuses on why women with dense breasts may need more than a screening mammogram. Miller highlights the recent story in People magazine of Jill Goodacre, a former Victoria’s Secret model and the wife of recording artist and talk show host Harry Connick Jr. Goodacre told of her breast cancer diagnosis 5 years ago after having additional screening of her dense breast tissue following a normal
Several guidelines help physicians decide when a woman should begin screening for breast cancer and how often she should be screened. However, are these guidelines put into use in the clinic? (8/8/17)
Routine breast cancer screening for women of average risk has been controversial for many years because some believe that the benefits do not outweigh the risks. Recent headlines covering a study in Denmark suggests that routine breast cancer screening leads to “overdiagnosis” of breast cancer. (4/4/17)
Some patients take longer than others before getting a potential breast cancer checked by their health care provider. Believing that women who have breast cancer symptoms but have no lump may wait longer, researchers in this study used data from women who were diagnosed with breast cancer in 2009 and 2010 to identify possible explanations. (1/18/17)
The United States Preventative Services Task Force (USPSTF) recommends a screening mammogram every other year for women ages 50-74 who are at average risk for breast cancer. But do all patients in this category benefit from this screening regimen?
In August 2016, many news outlets published stories about how actress Shannen Doherty’s dog was able to sniff out her cancer before she was diagnosed. Is there scientific validity to that claim? (9/616)
Some states offer women dense breast notifications that are meant to explain that dense breasts are risk factors for breast cancer and can hide cancer on mammograms, and to identify appropriate supplemental screening options. But recent research found that this information is often not easy to read or understand, which questions the usefulness of the documents. (6/7/16)
Mammography has been shown to reduce breast cancer deaths; however, women in developing countries don’t have easy access to mammography. Ultrasound screening, on the other hand, is portable and less expensive, and could be an alternative to mammography. This study compared mammography to ultrasound in women with dense breasts and found the two techniques have similar cancer detection rates, although the false positive rate is higher with ultrasound.
Multigene panel testing can look for mutations in many genes associated with increased cancer risk all in the same test. Some panels include genes associated with increased risk of multiple cancers, including breast, ovarian, colon, and gastric cancers. This study showed that results from multigene panel testing may change medical options for patients who test positive for a mutation linked to increased cancer risk. (9/22/15)